Live price temporarily unavailable.
TransCode Therapeutics (RNAZ) is a Health Care company. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$726.6K | −$6.15M | −$18.6M | −$19.4M | −$15.7M | −$28.0M |
| Net income | −$2.34M | −$6.84M | −$17.6M | −$18.5M | −$16.8M | −$34.7M |
| EPS (diluted) | −$10.20 | −$16.20 | −$1082.79 | −$3419.01 | −$1336.63 | −$52.59 |
| Balance sheet | ||||||
| Cash and equivalents | $828.0K | $20.8M | $4.97M | $2.77M | $5.81M | $17.8M |
| Total assets | $1.06M | $22.9M | $7.59M | $5.17M | $7.29M | $162.4M |
| Total liabilities | $4.46M | $2.53M | $4.35M | $3.53M | $9.31M | $10.5M |
| Shareholders' equity | −$3.41M | $20.4M | $3.24M | $1.64M | −$2.02M | $10.3M |
| Cash flow | ||||||
| Operating cash flow | −$493.0K | −$5.27M | −$15.8M | −$18.1M | −$13.3M | −$19.5M |
| Capital expenditure | — | $254.8K | $100.9K | $35.6K | $21.8K | $6.66K |
| Free cash flow | — | −$5.52M | −$15.9M | −$18.1M | −$13.4M | −$19.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$2.17M | −$5.09M | −$3.17M | −$4.22M | −$4.56M | −$16.0M | −$17.8M | −$6.79M |
| Net income | −$2.32M | −$5.92M | −$12.1M | −$4.28M | −$4.86M | −$13.4M | −$17.8M | −$6.75M |
| EPS (diluted) | −$146.06 | −$488.99 | −$70.16 | −$5.13 | −$5.82 | $28.52 | −$21.28 | −$7.17 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.88M | $5.81M | $11.6M | $7.37M | $2.84M | $17.8M | $12.8M | $8.38M |
| Total assets | $3.94M | $7.29M | $13.2M | $8.27M | $5.23M | $162.4M | $157.2M | $151.0M |
| Total liabilities | $2.28M | $9.31M | $2.90M | $2.12M | $3.80M | $10.5M | $12.6M | $12.7M |
| Shareholders' equity | $1.65M | −$2.02M | $10.3M | $6.15M | $1.43M | $10.3M | $1.25M | −$27.7M |
| Cash flow | ||||||||
| Operating cash flow | −$3.91M | −$3.15M | −$3.10M | −$4.19M | −$4.08M | −$8.14M | −$4.98M | −$5.40M |
| Capital expenditure | $12.9K | $500 | — | — | — | — | — | — |
| Free cash flow | −$3.93M | −$3.15M | — | — | — | — | — | — |
From TransCode Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning TransCode Therapeutics in our feed yet.